Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of “Buy” by Brokerages
Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have updated their coverage on […]
More Stories
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.50) earnings per...
LCI Industries (NYSE:LCII) to Issue Dividend Increase – $1.15 Per Share
LCI Industries (NYSE:LCII – Get Free Report) declared a quarterly dividend on Thursday, November 14th,RTT News reports. Shareholders of record...
CleanSpark (NASDAQ:CLSK) vs. Binah Capital Group (NASDAQ:BCG) Head-To-Head Comparison
CleanSpark (NASDAQ:CLSK – Get Free Report) and Binah Capital Group (NASDAQ:BCG – Get Free Report) are both finance companies, but...
ADVFN (LON:AFN) Shares Down 8.1% – What’s Next?
ADVFN Plc (LON:AFN – Get Free Report)’s share price dropped 8.1% during mid-day trading on Thursday . The company traded...
ICC Labs (CVE:ICC) Trading Down 5.8% – What’s Next?
ICC Labs Inc. (CVE:ICC – Get Free Report) dropped 5.8% during mid-day trading on Thursday . The stock traded as...
Vanguard Core Bond ETF (NASDAQ:VCRB) Short Interest Update
Vanguard Core Bond ETF (NASDAQ:VCRB – Get Free Report) was the target of a large growth in short interest in...